NCT02556762View on ClinicalTrials.gov

Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 1, 2022

Study Completion Date

December 31, 2024

Conditions
Esophageal Cancer
Interventions
RADIATION

Radiotherapy with simultaneous modulated accelerated boost

Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases

RADIATION

Standard dose radiotherapy

Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease

DRUG

PF

Chemotherapy: Cisplatin and 5fluorouracil

Trial Locations (1)

515031

Cancer Hospital, Shantou University Medical College, Shantou

All Listed Sponsors
lead

Chuangzhen Chen

OTHER